Over 5 million people die each year from viral diseases.
2 billion people lack access to essential medicines.
Only 1% of new drugs developed in the last 30 years target neglected diseases.
The International Consortium on Anti-Virals (ICAV) is a not-for-profit drug development organization dedicated to the discovery and development of anti-viral therapies for neglected and emerging diseases.
ICAV’s goal is to deliver one drug to market every five years that is affordable, effective, and accessible to all patients in need.
H1N1 Resource and Updates
A new ICAV site for Influenza H1N1 virus: background, updates and discoveries
News
September 25, 2009
CAV/CITAV Receives Second Round Of Funding From Public Health Agency Of Canada
Full article
Interviews of Jeremy Carver on CHEXTV about the A H1N1 virus.
Interview of May 7, 2009
Interview of April 27, 2009
May 14, 2009
The International Consortium on Anti‐Virals/Consortium International sur les Thérapies Anti‐Virales (ICAV/CITAV) congratulates its Co‐Founder, Dr Michel Chrétien on his election to the Royal Academy, London.
Full article
[ More news…]
Upcoming events
More details to follow
Past events
Information about the Beijing meeting.
Information about the Peterborough meeting.
News from the World Health organization
| Mon, 08 Feb 2010 09:00:00 GMT |
| Avian influenza - situation in Egypt - update 28 |
| Full text |
| Mon, 08 Feb 2010 08:00:00 GMT |
| Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO |
| Full text |
| Thu, 28 Jan 2010 09:00:00 GMT |
| Avian influenza - situation in Egypt - update 27 |
| Full text |
| Thu, 28 Jan 2010 08:00:00 GMT |
| Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO |
| Full text |